Patents by Inventor Yong-Je Shin

Yong-Je Shin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240051951
    Abstract: The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.
    Type: Application
    Filed: June 8, 2023
    Publication date: February 15, 2024
    Inventors: Yong Je SHIN, Jin Hee KIM, Jun LEE, Sook Kyung PARK, Ho Yeon LEE, Hyun Suk CHOI, Se Hyuk KIM, Eun Ji KANG, Ho Youl LEE, Soo Yeon JUNG
  • Publication number: 20230286965
    Abstract: The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present disclosure can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.
    Type: Application
    Filed: March 17, 2023
    Publication date: September 14, 2023
    Inventors: Yong Je SHIN, Jin Hee KIM, Jun LEE, Sook Kyung PARK, Ho Yeon LEE, Hyun Suk CHOI, Se Hyuk KIM, Eun Ji KANG, Ho Youl LEE, Soo Yeon JUNG
  • Patent number: 11725001
    Abstract: The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: August 15, 2023
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Yong Je Shin, Jin Hee Kim, Jun Lee, Sook Kyung Park, Ho Yeon Lee, Hyun Suk Choi, Se Hyuk Kim, Eun Ji Kang, Ho Youl Lee, Soo Yeon Jung
  • Publication number: 20230023140
    Abstract: The present invention relates to a 6-6 bicyclic ring-containing compound derivative and use thereof. The compound according to the present invention acts as a PRMT5 inhibitor, and thus can be effectively used in the prevention or treatment of diseases caused by PRMT5.
    Type: Application
    Filed: October 22, 2020
    Publication date: January 26, 2023
    Inventors: Yong Je SHIN, Jin Hee KIM, Jun LEE, Hyun Suk CHOI, Se Hyuk KIM, Eun Ji KANG, Sook Kyung PARK, Ho Youl LEE, Ho Yeon LEE
  • Publication number: 20220402902
    Abstract: The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.
    Type: Application
    Filed: July 19, 2021
    Publication date: December 22, 2022
    Inventors: Yong Je SHIN, Jin Hee KIM, Jun LEE, Sook Kyung PARK, Ho Yeon LEE, Hyun Suk CHOI, Se Hyuk KIM, Eun Ji KANG, Ho Youl LEE, Soo Yeon JUNG
  • Publication number: 20210300933
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: June 1, 2021
    Publication date: September 30, 2021
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • Patent number: 11111237
    Abstract: The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: September 7, 2021
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Yong Je Shin, Jin Hee Kim, Jun Lee, Sook Kyung Park, Ho Yeon Lee, Hyun Suk Choi, Se Hyuk Kim, Eun Ji Kang, Ho Youl Lee, Soo Yeon Jung
  • Patent number: 11046702
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: June 29, 2021
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
  • Publication number: 20210101892
    Abstract: The present disclosure relates to a compound derivative containing a 6-7 bicyclic ring and use thereof. The compound according to the present invention can be effectively used in the prevention or treatment of diseases caused by PRMT5 by acting as a PRMT5 inhibitor.
    Type: Application
    Filed: November 24, 2020
    Publication date: April 8, 2021
    Inventors: Yong Je SHIN, Jin Hee KIM, Jun LEE, Sook Kyung PARK, Ho Yeon LEE, Hyun Suk CHOI, Se Hyuk KIM, Eun Ji KANG, Ho Youl LEE, Soo Yeon JUNG
  • Publication number: 20200277298
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: April 17, 2020
    Publication date: September 3, 2020
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • Publication number: 20190031669
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: September 28, 2018
    Publication date: January 31, 2019
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • Patent number: 10100057
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 16, 2018
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
  • Publication number: 20170349597
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: July 31, 2017
    Publication date: December 7, 2017
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • Patent number: 9745310
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: August 29, 2017
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Chun Eung Park, Young Koo Jang, Yong Je Shin, Ji Yeon Kim, Seung Mo Ham, Yong Gil Kim, Hye Kyung Min, Soo Bong Cha, Hyo Jun Jung, Ju Young Lee, Seung Nam Han, Jin Yong Chung, Eun Ju Choi, Chan Mi Joung, Jong Sil Park, Ji Won Lee, Nahm Ryune Cho, Eun Ju Ryu, Cheol Young Maeng
  • Publication number: 20160251361
    Abstract: The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: wherein X, Z, R1 and R2 are as defined in the specification. The compound of Chemical Formula (1) or pharmaceutically acceptable salt thereof acts as a positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5), thereby being useful in the prevention or treatment of disorder mediated by glutamate dysfunction and mGluR5.
    Type: Application
    Filed: February 25, 2016
    Publication date: September 1, 2016
    Inventors: Chun Eung PARK, Young Koo JANG, Yong Je SHIN, Ji Yeon KIM, Seung Mo HAM, Yong Gil KIM, Hye Kyung MIN, Soo Bong CHA, Hyo Jun JUNG, Ju Young LEE, Seung Nam HAN, Jin Yong CHUNG, Eun Ju CHOI, Chan Mi JOUNG, Jong Sil PARK, Ji Won LEE, Nahm Ryune CHO, Eun Ju RYU, Cheol Young MAENG
  • Patent number: 8546576
    Abstract: There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds. The subject compounds are useful for the treatment of diseases of the central nervous system, particularly depression, anxiety and pain disorder.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: October 1, 2013
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Ki-Ho Lee, Chun-Eung Park, Kyung-Hyun Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu
  • Patent number: 8513285
    Abstract: There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds. The subject compounds are useful for the treatment of diseases of the central nervous system, particularly depression, anxiety and pain disorder.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: August 20, 2013
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Ki-Ho Lee, Chun-Eung Park, Kyung-Hyan Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu
  • Patent number: 8404730
    Abstract: Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: March 26, 2013
    Assignee: SK Biopharmaceuticals Co., Ltd.
    Inventors: Chun-Eung Park, Kyung-Hyun Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu, Coo-Min Chung, Hui-Ho Kim
  • Publication number: 20120122927
    Abstract: There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): or any of their isomers, or pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions containing the subject compounds.
    Type: Application
    Filed: January 19, 2012
    Publication date: May 17, 2012
    Inventors: Ki-Ho Lee, Chun-Eung Park, Kyung-Hyan Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu
  • Publication number: 20120046312
    Abstract: Racemic or enantiomerically enriched 3-substituted propanamine compounds represented by the following structural formula (I): or a pharmaceutically acceptable salt thereof are disclosed. Pharmaceutical compositions containing the subject compounds are also disclosed. The subject compounds are useful for the treatment of diseases of the central nervous system, such as depression, anxiety and pain disorders.
    Type: Application
    Filed: October 19, 2011
    Publication date: February 23, 2012
    Inventors: Chun-Eung Park, Kyung-Hyun Min, Yong-Je Shin, Yu-Jin Shin, Hae-Jeong Yoon, Won Kim, Eun-Ju Ryu, Coo-Min Chung, Hui-Ho Kim